PCNSL
A New Target for Tisagenlecleucel: Primary Central Nervous System Lymphoma
Ariel DeMaioPrint | November 29, 2022
Tisagenlecleucel was well-tolerated with manageable toxicity in patients with primary central nervous system lymphoma.
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |